The safety and liver utilization with prerecovery liver biopsy (PLB) in extended criteria liver donors are unclear. We conducted a retrospective cohort study in 1323 brain death donors (PLB 5 496) from 3 organ procurement organizations (OPOs). Outcomes were complications, preempted liver recovery (PLR), and liver transplantation (LT). Additional analyses included liveronly and propensity score-matched multiorgan donor subgroups. PLB donors were older (57 versus 53 years; P < 0.001). Hepatitis C antibody positivity (14.3% versus 9.6%, P 5 0.01) and liver-only donors (42.6% versus 17.5%; P < 0.001) were more prevalent. The PLB cohort had fewer complications (31.9% versus 42.3%; P < 0.001). In the PLB cohort, PLR was significantly higher (odds ratio [OR], 3.45; 95% confidence interval [CI], 2.42-4.92) and LT lower (OR, 0.69; 95% CI, 0.52-0.91). In liver-only and propensity score-matched multiorgan donor subgroups, PLR was significantly higher (OR, 1.76; 95% CI, 1.06-2.94 and OR, 2.29; 95% CI, 1.37-3.82, respectively) without a decrease in LT (OR, 0.71; 95% CI, 0.43-1.18 and OR, 0.91; 95% CI, 0.63-1.33, respectively) in PLB subgroups. In conclusion, in extended criteria liver donors, PLB is safe and decreases futile liver recovery without decreasing LT. Increased use of PLB, especially in liver-only donors, is likely to save costs to OPOs and transplant centers and improve efficiencies in organ allocation.
acceptable donor livers.
(1-3) However, the deceased donor pool is becoming older, more obese, with a higher prevalence of diabetes, which increases the risk of primary nonfunction, early allograft dysfunction, and decrease in longterm graft survival. (4) (5) (6) Between 2004 and 2010, the nonutilization rate of livers increased from 15% to 21%. (7) Transplant centers use a combination of donor history and laboratory tests, and in some instances liver imaging, to evaluate a given liver donor. A liver biopsy is often the final determinant in selection for transplantation. (8) Therefore, it is not surprising that the most common reasons for "liver discards" are biopsy findings. (9) Steatosis of > 30% is associated with 11-fold higher odds of liver nonuse. (7) In addition, histological findings of chronic liver disease, cirrhosis, and ischemia are commonly reported reasons for not using livers. (10) Liver biopsy in brain death donors is most often performed during organ recovery. (11, 12) An intraoperative liver biopsy, although safe and easy to perform with reliable sampling, delays the decision of whether to use the liver or not until liver recovery commences. An alternative would be to perform a liver biopsy prior to organ recovery. Availability of biopsy information well before organ recovery commences may not only decrease futile liver recovery and decrease unnecessary costs, but it may also improve efficiency of liver allocation and increase the rate of transplantation of extended criteria livers.
Our recent survey of all American organ procurement organizations (OPOs) revealed that 80% perform prerecovery liver biopsy (PLB). However, the median rate of PLB is only in 5%-10% of potential brain death organ donors. (13) That is in contrast to an almost 30% rate of intraoperative biopsy. (14) Evidence from 3 single OPO studies suggests that PLB decreases futile liver recovery and may be cost-effective, particularly in liveronly donors. (15) (16) (17) There are no large studies confirming this and the safety of PLB. Therefore, a multi-OPO study was conducted to test the hypotheses that PLB is safe, decreases futile liver recovery, and increases utilization of extended criteria livers.
Patients and Methods
This study was conducted in 3 geographically distant and demographically diverse OPOs: Texas Organ Sharing Alliance (TOSA), New York Organ Donor Network (NYODN), and Gift of Life Michigan (GLM). Table 1 describes the donor service area and other pertinent characteristics including biopsy criteria within the OPO. The study protocol was approved by the Rutgers University-New Jersey Medical School Institutional Review Board (Pro2012001410) as well each OPO research committee. This manuscript conforms to the guidelines recommended in the STrengthening the Reporting of Observational Studies in Epidemilogy (STROBE) statement checklist. population. The unbalance in the number of years included was due to differences in the overall number of donors and the proportion having PLB among the OPOs. Increased risk for liver disease was defined as the presence of at least 1 of the following factors: morbid obesity (body mass index [BMI] 35 kg/m 2 ), history of diabetes or alcohol abuse, hepatitis B or C seropositivity, or advanced donor age (age 60 years). All donor records were reviewed either by the study team (TOSA and NYODN) or by the OPO staff (GLM) to include all atrisk donors. From this larger group of "at-risk" donors, cohorts in whom a PLB was and was not performed were identified. Study team (J.B.O., P.M., T.P.) abstracted the data, and 1 member (J.B.O.) audited all data.
STUDY DATA
Information regarding demographic, laboratory, hemodynamic, and recovery/transplantation data was extracted from donor records. Laboratory and vital signs data immediately prior to PLB or at initiation of care by the OPO were used as baseline measurements in PLB and No PLB cohorts, respectively. Initiation of care by OPO was assumed to be upon declaration of death by neurologic criteria and consent for organ donation. When indication for PLB was not explicit, the most plausible reason(s) based on the clinical information was used. Because of limitations in the OPO records, information regarding performance of the biopsy (who and how) and who interpreted the PLB was not available. Findings of PLB were provided to transplant centers through 1 or more modes of telephone, facsimile of reports, and/or DonorNet (United Network for Organ Sharing, Richmond, VA). Information regarding the centers in donor liver allocation sequence and specific reasons for declination of livers-except due to "biopsy"-were not available. Allocation was as per the standard practices. Often livers were shared with "aggressive centers" if declined, either preoperatively or intraoperatively, by all centers within the sequence generated by United Network for Organ Sharing. The PLB and intraoperative biopsy slides were not archived at the OPOs. Hence an independent review of the biopsies was impractical for this study.
OUTCOMES
The primary safety outcome was a composite of either 1 or a combination of the following: a decrease in the hemoglobin level >2 g/dL, a decrease in the mean arterial pressure (MAP) > 30 mm Hg, and/or a blood transfusion, within 24 hours of biopsy. In the No PLB cohort, a 24-hour period of evaluation from the time of initiation of care by the OPO was used. The secondary outcomes were the individual components of the primary outcome, cardiac arrest prior to organ recovery, and injury to the liver because of PLB. To evaluate liver discards/utilization, 3 mutually exclusive primary outcomes were evaluated in each donor:
1. Liver recovery was ruled out before organ recovery commenced (preempted liver recovery [PLR]). 2. Liver recovery without transplantation (RWT). 3. Liver transplantation (LT) was completed.
The first outcome was used to test the hypothesis that PLB decreases futile liver recovery. The last outcome was used to test the hypothesis that PLB increases transplantation of extended criteria livers. All analyses were conducted for the entire study, individual OPO, and for each risk factor including liver-only donors. In addition, each clinical outcome was examined in propensity score-matched multiorgan donor cohorts.
PROPENSITY SCORE MATCHING
We used propensity score matching to adjust for the imbalances in risk factors for liver discards/utilization between PLB and no PLB cohorts. Propensity scores were calculated using PROC LOGISTIC in SAS, version 9.3 (SAS Institute, Cary, NC). Variables used include OPO, donor age, BMI, history of diabetes, hypertension, alcohol abuse, intravenous (IV) drug use, and hepatitis B and C serologies. The 2 cohorts were stratified into multiorgan and liver-only donors and matched 1:1 with the OneToManyMTCH macro for SAS. (19) Among 284 in the multiorgan PLB cohort, 278 had complete information to undergo matching, and 259 matches were made (93% match rate, c value 5 0.71). Propensity score matching in liver-only donors could not be completed due to the disproportionate number of liver-only donors within the PLB cohort and a poor match rate.
STATISTICAL ANALYSES
Continuous data are presented as means and standard deviations (SDs) or as medians with interquartile ranges (IQRs). Discrete data are presented as counts and percentages. The significance of differences between groups was tested with either the Student t test/analysis of variance or the Mann-Whitney U test/ Kruskal Wallis for continuous data and with chi-square for discrete data. The clinical outcomes were compared globally via chi-square. For individual outcomes, odds ratios (ORs) were calculated using No PLB cohort as reference. To control for confounding, multivariate conditional logistic regressions were used to calculate ORs for complications, PLR, and livers transplanted with adjustment for differences in demographics, laboratory values, and risk factors. For model building, all variables in Table 2 were compared with the outcome(s) in univariate models and candidate variables were those with P < 0.2. Collinearity between variables was examined with bivariate correlations. Among those with r > 0.7, the variable with a more significant association was included in model building. Models were built in a backward fashion, removing nonsignificant predictors based on the smallest Wald value, and the model with the best Akaike information criterion was used. Model fit was assessed using c statistic. Models were evaluated with and without influential and significant outlier cases. Subgroup analyses were performed based on OPO and indications for biopsy. P values < 0.05 were considered significant. In the analyses of matched data, categorical variables were compared with CochranMantel-Haenszel methods and continuous variables were compared with matched t tests or Wilcoxon signed rank tests. ORs were calculated with conditional logistic regression. All statistics were calculated using SAS, version 9.3.
SAMPLE SIZE
Sample size calculations were performed a priori with an alpha of 0.05 and 80% power. To detect an increase in PLR from 10% to 20% without a change in the rate of livers transplanted required 199 donors in each arm. To detect an increase in LT from 60% to 70% required 356 donors in each arm. 
Results

PLB AND NO PLB COHORTS DIFFER IN BASELINE DEMOGRAPHICS AND RISK FACTORS
The PLB cohort comprised 496 donors and the No PLB cohort 827 donors. Significant differences existed between the 2 cohorts regarding potential indications for PLB (Table 2) . PLB donors had a significantly higher prevalence of hypertension, hepatitis C antibody (Ab) positivity, and liver-only donors, and were also significantly older. The mean 6 SD duration of donor management was significantly longer in the PLB cohort regardless of whether organ recovery was (27.9 6 10.5 versus 25.2 6 12.6 hours; P < 0.001) or was not (23.8 6 12.4 versus 17.7 6 14.9 hours; P < 0.001) pursued. The intervals between incision and aortic cross-clamp in the 2 groups were not significantly different (87.4 6 44.0 versus 91.8 6 52.5 minute; P 5 0.15). Laboratory values were comparable between the 2 cohorts.
OPO Level
Composition of PLB and No PLB cohorts was 74/ 179 at TOSA, 203/378 at NYODN, and 219/270 at GLM. PLB and No PLB cohorts were similar except for higher prevalence in the PLB cohorts of diabetes within NYODN (37.9% versus 26.4%; P < 0.001); hypertension within GLM (57.8% versus 48.7%; P 5 0.046), NYODN (71.4% versus 58.3%; P 5 0.002), and TOSA (63.0% versus 49.4%; P 5 0.049); alcohol abuse in NYODN (18.2% versus 26.5%; P 5 0.03); hepatitis C Ab positivity in TOSA (21.0% versus 9.4%; P 5 0.02); and liver-only donors in NYODN (71.4% versus 24.2%; P < 0.001) and TOSA (41.9% versus 13.4%; P < 0.001).
Notable differences existed within the PLB cohort among the 3 OPOs (Supporting Table 1 ). NYODN had the highest percent of African American donors, GLM had the highest percent of white donors, and TOSA had the highest percent of Hispanic donors. Donors were older, had higher prevalence of diabetes, positive hepatitis B core Ab status, and liver-only donors and lower prevalence of alcohol abuse in NYODN. Donors in GLM had a lower prevalence of hypertension. These differences were all significant.
PLB IS NOT ASSOCIATED WITH INCREASED COMPLICATIONS DURING DONOR MANAGEMENT
Study level comparison of complications between the 2 cohorts is shown in Fig. 1 . A total of 6 (1.2%) and 19 (2.3%) donors were lost due to cardiac arrest from hemodynamic instability in PLB and No PLB cohorts, respectively (P 5 0.16). In the PLB cohort, 2 livers (0.4%) were not transplanted directly due to PLB, 1 due to a large hematoma, and another due to bile duct injury. The donor with a large hematoma was a 72-year-old with hypertension and a normal BMI. Prebiopsy laboratory values were hemoglobin 13.3 g/dL, platelets of 196,000/mm 3 , and international normalized ratio (INR) 1.2. The liver had minimal macrosteatosis (1%-15%), minimal inflammation, and no fibrosis. After biopsy, the hemoglobin decreased to 4.4 g/dL and the donor required multiple transfusions. The donor with a bile duct injury was a 60-year-old with a BMI of 29 kg/m 2 and had no other comorbidities. Liver chemistries were normal. The biopsy revealed 5% macrosteatosis without fibrosis or inflammation. At laparotomy, bile was present throughout the abdomen. The liver was deemed not transplantable.
In univariate analysis, the composite complication rate was significantly lower in the PLB cohort (31.9% versus 42.3%; P < 0.001) for the entire study. At an OPO level, the rates in PLB and No PLB cohorts Figure 2 demonstrates study wide liver recovery outcomes. (Fig. 3) . Additional analyses were performed to identify characteristics associated with the study wide clinical outcome of PLR in both PLB and No PLB cohorts. The 5 most prevalent indicators in all PLR donors were age over 50 years, liver-only recovery, alcohol use, diabetes, and positive hepatitis C serology (Supporting Table 2 ). In a comparison of PLR subgroups in both cohorts, alcohol use, hepatitis virus seropositivity, and abnormal liver chemistries were more prevalent and diabetes, hypertension, and liver-only recovery were 
PLB IS ASSOCIATED WITH A DECREASE IN FUTILE LIVER RECOVERY
PLB IS ASSOCIATED WITH A DECREASE IN THE PROPORTION OF LIVERS TRANSPLANTED IN UNMATCHED ANALYSES
Fewer (49%) livers were transplanted from the PLB cohort in comparison to the No PLB cohort (65%, Fig. 2 ; P < 0.001; Table 3 ). Importantly, in multivariate analysis, the odds of LT were one-third lower in the PLB cohort (OR, 0.67; 95% CI, 0.51-0.89; 
CLINICAL OUTCOMES WERE SIMILAR ACROSS DIFFERENT INDICATIONS FOR PLB
As might be expected, the indications for PLB are more than 1 in many cases. The overall trend of the outcomes remains consistent between each indication (Table 4) . Importantly, although PLB was associated with a significant increase in odds of PLR in each indication, it was not associated with a significant difference in the odds of LT.
IN PROPENSITY SCORE-MATCHED MULTIORGAN DONORS, LT RATES WERE SIMILAR IN PLB AND NO PLB COHORTS
Propensity score matching accomplished balancing of donor characteristics in both cohorts (n 5 259 each) of multiorgan donors (Supporting Table 3 
IN LIVER-ONLY DONORS, PLB IS ASSOCIATED WITH DECREASED FUTILE RECOVERY WITHOUT A SIGNIFICANT DIFFERENCE IN TRANSPLANTATION RATES
Supporting Table 4 shows the baseline characteristics of the liver-only donors in the 2 cohorts. The PLB donors were older but otherwise the 2 groups were comparable. In the PLB cohort (n 5 211), LT occurred from 67 (31.8%), PLR in 107 (50.7%), and RWT in 37 (17.5%) in comparison to 59 (41.0%), 54 (37.5%), and 31 (21.5%), respectively in the No PLB cohort (n 5 144). Odds of LT were similar between the cohorts (OR, 0.71; 95% CI, 0.43-1.18; P 5 0.19), whereas the odds for PLR (OR, 1.76; 95% CI, 1.06-2.94; P 5 0.04) favored the PLB group. NOTE: More than 1 indication for biopsy existed in many cases. Bold is significant at P < 0.05.
Discussion
Despite the use of PLB in brain death donors in many OPOs in the United States, the existing literature on this topic is sparse. Our large study provides substantially more information on the important issues of safety, futile liver recovery, and liver utilization than the existing 3 single-center-based publications. (15) (16) (17) The multifaceted diversity in the OPOs and their donor population allow for greater generalizability of our findings.
The first important finding of our study is that PLB is overall safe in brain death donors. This confirms the findings of an earlier study. (15) However, the complications rate of 32% with PLB in the current study is much higher than the 9% reported previously. (15) The increased rate of complications in both cohorts in the present study is very likely due to OPO donor management practices, especially the transfusion practices. Importantly, the finding that the complication rate is significantly higher in the No PLB cohort is very likely spurious. This aberrant finding is most likely related to performance of PLB in more "stable" donors and commencement of 24 hours of study-related assessment in the No PLB cohort from the time of death pronouncement-a period when the clinical effects of brain death pathophysiology are most evident. The most concerning safety item was that PLB directly led to the discard of 2 transplantable livers. Although the overall percentage of PLB-induced liver loss is small, such experiences are very likely to hinder a wider use of PLB. Whether such serious complications from PLB can be avoided with systematized biopsy practices, such as routine use of image-guidance and performance of PLB by interventional radiologists or trained OPO personnel require additional investigations.
The second important finding of this study is that PLB is associated with a decrease in futile liver recovery. This is substantiated by the 3.5-fold higher odds of PLR in the PLB cohort. Furthermore, their association persisted across all clinical indications, and in both liver-only and propensity score-matched multiorgan donors. Previously, in smaller studies of liver-only donors, Ganz et al. showed that PLB findings led to 12 PLR decisions in 21, (16) while Mangus et al. reported 37 PLR decisions in 110. (17) Similarly, in our previous study, PLR rates were 30% in the PLB group in comparison to 9% in matched controls. (15) Collectively, the findings show that PLB shifts the decision making about liver usability from the operating room to the bedside in several of the donors. The questions whether the clinical information without a biopsy would have been adequate to reach a PLR decision and to what extent did PLB contribute to reach the PLR decisions remain unanswered.
Prerecovery decisions about liver usability have potential economic implications. In a 2001 study, OPO cost savings of $5600 were projected when RWT was avoided by PLB. (16) A more recent study estimated OPO cost savings of $10,000 from prevention of each RWT versus cost of $500 per biopsy. (17) The OPO cost savings from avoidance of RWT is likely to be substantially less in multiorgan than in liver-only donors. Surgical fees and transplant center costs were not included in the above analyses. Additional studies are needed to address the OPO and transplant center costs associated with futile liver recovery, especially considering current wider regional sharing, and would be important in assessments of utility of PLB.
The third and the most important finding of our study is that PLB use is not associated with a change in liver utilization rates in extended criteria liver donors. Our unmatched study wide analyses showed a decrease in liver utilization in the PLB cohort. Understandably, such a finding would raise a serious concern but must be interpreted with caution. Because of the inherent selection bias, livers from the PLB cohort are likely to be truly less transplantable than livers from the No PLB cohort. It is unlikely that multivariate analyses adequately addressed the imbalances between the 2 cohorts in risk variables that impact liver utilization. For example, information regarding the duration of diabetes or alcohol abuse, which was potentially used in making decisions regarding PLB, was not available. In NYODN, the OPO with a significantly lower rate of transplantation in PLB donors, many donors were prescreened with liver imaging and the findings were used in decisions regarding PLB. Credence to our argument is provided by the findings in subgroup analyses of multiorgan and liver-only donors. When imbalances in known risk characteristics were either adequately matched (propensity score-matched multiorgan donors) or substantially reduced (liver-only donors), liver utilization rates were similar whether PLB was or was not performed. However, it is noteworthy, in 2 of the larger OPOs, fewer livers are transplanted in the PLB cohort in adjusted analyses. It is only when the smaller and the third OPO is included-in the study wide analyses-that the difference in LT becomes insignificant. Within propensity score matching, these center-specific differences disappear.
The most important and serious concern regarding our findings is whether the PLB-based decisions of PLR led to erroneous exclusion of some livers from transplantation. This is very pertinent given the scarcity of livers and the current aggressive standard practice of evaluation of marginal livers at laparotomy, and only declining livers based on naked eye evaluation and histological findings. At the core of this concern is the issue of the reliability of PLB findings. In a recent survey in the United States, this concern was a major reason OPOs provided for not performing PLB. (13) Use of PLB is likely to increase if its findings are considered reliable and accurate in comparison to intraoperative biopsies. (12) Data in the literature in other clinical contexts show that percutaneous liver biopsies are overall reliable and interbiopsy comparisons are accurate. (20, 21) However, reliability is dependent on the number and size of the needle cores. Performance and comparison of intraoperative biopsy with the PLB in the subgroup of PLB donors that proceeded to recovery would have offered an excellent opportunity to assess the accuracy and reliability of PLB. Inability to conduct a histological review of PLB and the related problem of comparison of PLB to intraoperative biopsies is a serious limitation in addressing the conjoined issues of PLR and LT. In future studies, comparison of PLB with intraoperative biopsies should be an important component. Lack of additional information such as travel distances for liver recovery and transplant teams, how much effort the OPOs exerted to place the livers, and the results of allocation match runs, once the PLB findings became available, are additional limitations that are relevant to the PLR issue.
Our study has other limitations. Indications for PLB varied across the OPOs (Table 1) introducing a major selection bias. Despite propensity score matching and multivariate adjusted analyses, concerns remain regarding other unaccounted differences between the PLB and No PLB cohorts and their association with the PLR and LT outcomes. As an example, even among the donors with the clinical indications, PLB was unlikely to have been performed in those with hemodynamic instability. Items such as this and others were not accounted for in the analyses. Information in the OPO records is incomplete. Examples include lack of documentation of reasons for not doing PLB in otherwise "indicated" donors, lack of details of PLB findings, and sequence of programs that livers were offered to, and so on. Pursuit of additional information in donor hospital records, obtaining biopsy slides, and liver allocation match runs was logistically prohibitive.
Our study leads us to the following conclusions. First, although the current safety profile of PLB is satisfactory, there is room for further improvement. Attainment of a safety profile of no loss of livers or any other transplantable organs due to complications from PLB would be important before wider use of PLB in all extended criteria donor livers. Second, to help address the issue of reliability of PLB, we propose that OPOs that currently use PLB also perform intraoperative biopsies in all operating room-bound donors and create opportunities for comparison of the 2 sets. Third, PLB has the potential to save OPO and transplant center costs arising from futile liver recovery, especially in liveronly donors. We propose a wider use of PLB in liveronly donors with 1 or more of the following risk variables: alcohol abuse, positive hepatitis serology, advanced age, obesity, and diabetes. The role of PLB in multiorgan donors is unclear. Finally, OPOs should explore the use of web-based dissemination of biopsy images to the transplant centers in the allocation sequence. This offers the potential to increase efficiencies in allocation of extended criteria livers.
